PMADS

Id:	acc3878
Group:	1sens
Protein:	cPLA2
Gene Symbol:	PLA2G4A
Protein Id:	P47712
Protein Name:	PA24A_HUMAN
PTM:	phosphorylation
Site:	unclear
Site Sequence:
Disease Category:	Digestive system diseases
Disease:	Periodontal Disease
Disease Subtype:	"Gingival Inflammation,Periodontal Disease"
Disease Cellline:
Disease Info:
Drug:	Orento
Drug Info:	"Orento is a drug that may be used for specific medical purposes. However, more detailed information about its functions and indications requires further data. "
Effect:	modulate
Effect Info:	"Orento inhibits the phosphorylation of ERK, which in turn inhibits the phosphorylation and activation of cPLA2, reduces the production of PGE2, helps relieve gingival inflammation, and improves the condition of periodontal disease."
Note:
Score:	4.0
Pubmed(PMID):	20410594
Sentence Index:	20410594_10
Sentence:	"These results suggest that Orento decreased PGE(2) production by inhibition of cPLA(2) phosphorylation and its activation via inhibition of ERK phosphorylation, and also that Orento may be useful to improve gingival inflammation in periodontal disease."

Sequence & Structure:

MSFIDPYQHIIVEHQYSHKFTVVVLRATKVTKGAFGDMLDTPDPYVELFISTTPDSRKRTRHFNNDINPVWNETFEFILDPNQENVLEITLMDANYVMDETLGTATFTVSSMKVGEKKEVPFIFNQVTEMVLEMSLEVCSCPDLRFSMALCDQEKTFRQQRKEHIRESMKKLLGPKNSEGLHSARDVPVVAILGSGGGFRAMVGFSGVMKALYESGILDCATYVAGLSGSTWYMSTLYSHPDFPEKGPEEINEELMKNVSHNPLLLLTPQKVKRYVESLWKKKSSGQPVTFTDIFGMLIGETLIHNRMNTTLSSLKEKVNTAQCPLPLFTCLHVKPDVSELMFADWVEFSPYEIGMAKYGTFMAPDLFGSKFFMGTVVKKYEENPLHFLMGVWGSAFSILFNRVLGVSGSQSRGSTMEEELENITTKHIVSNDSSDSDDESHEPKGTENEDAGSDYQSDNQASWIHRMIMALVSDSALFNTREGRAGKVHNFMLGLNLNTSYPLSPLSDFATQDSFDDDELDAAVADPDEFERIYEPLDVKSKKIHVVDSGLTFNLPYPLILRPQRGVDLIISFDFSARPSDSSPPFKELLLAEKWAKMNKLPFPKIDPYVFDREGLKECYVFKPKNPDMEKDCPTIIHFVLANINFRKYRAPGVPRETEEEKEIADFDIFDDPESPFSTFNFQYPNQAFKRLHDLMHFNTLNNIDVIKEAMVESIEYRRQNPSRCSVSLSNVEARRFFNKEFLSKPKA

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target	Drug name	MOA	Phase	Status	Disease	Source
PLA2G4A	GIRIPLADIB	Cytosolic phospholipase A2 inhibitor	2	Terminated	osteoarthritis	ClinicalTrials
PLA2G4A	GIRIPLADIB	Cytosolic phospholipase A2 inhibitor	1	Completed	rheumatoid arthritis	ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

PLA2G4A-Ser371
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	-0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC	0.707
UCEC

PLA2G4A-Ser374
Cancer	Intensity
BRCA	1.326
COAD	-1.37
HGSC
ccRCC	0.181
GBM	-0.663
HNSC
LUAD
LUSC	-0.352
non_ccRCC
PDAC	0.878
UCEC

PLA2G4A-Ser375
Cancer	Intensity
BRCA	1.233
COAD	-1.207
HGSC
ccRCC	-0.041
GBM	1.152
HNSC
LUAD
LUSC	-0.417
non_ccRCC
PDAC	-0.721
UCEC

PLA2G4A-Ser377
Cancer	Intensity
BRCA	-2.022
COAD	0.328
HGSC	1.341
ccRCC	0.333
GBM	0.122
HNSC
LUAD
LUSC	-0.063
non_ccRCC	-0.681
PDAC	0.642
UCEC

PLA2G4A-Ser394
Cancer	Intensity
BRCA
COAD	0.707
HGSC
ccRCC
GBM	-0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PLA2G4A-Ser431
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	0.918
LUAD	-1.065
LUSC
non_ccRCC
PDAC
UCEC	0.147

PLA2G4A-Ser434
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	0.686
LUAD	0.461
LUSC
non_ccRCC
PDAC
UCEC	-1.147

PLA2G4A-Ser435
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	1.149
LUAD	-0.671
LUSC
non_ccRCC
PDAC
UCEC	-0.478

PLA2G4A-Ser437
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	0.928
LUAD	-1.059
LUSC
non_ccRCC
PDAC
UCEC	0.131

PLA2G4A-Ser454
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	-0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC	0.707

PLA2G4A-Ser664
Cancer	Intensity
BRCA	-0.289
COAD
HGSC
ccRCC	-0.824
GBM
HNSC
LUAD
LUSC	1.113
non_ccRCC
PDAC
UCEC

PLA2G4A-Ser667
Cancer	Intensity
BRCA	-1.006
COAD	0.351
HGSC	1.741
ccRCC	-0.493
GBM	0.321
HNSC
LUAD
LUSC	0.417
non_ccRCC	-1.51
PDAC	0.18
UCEC

PLA2G4A-Ser669
Cancer	Intensity
BRCA	-0.788
COAD	0.135
HGSC	2.176
ccRCC	-0.223
GBM	0.191
HNSC
LUAD
LUSC	0.2
non_ccRCC	-0.656
PDAC	-1.035
UCEC

PLA2G4A-Ser724
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	-0.42
LUAD	-0.721
LUSC
non_ccRCC
PDAC
UCEC	1.142

PLA2G4A-Ser727
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	1.142
LUAD	-0.425
LUSC
non_ccRCC
PDAC
UCEC	-0.717

PLA2G4A-Ser729
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	0.849
LUAD	0.254
LUSC
non_ccRCC
PDAC
UCEC	-1.102

PLA2G4A-Thr208
Cancer	Intensity
BRCA
COAD
HGSC	0.511
ccRCC	-1.156
GBM	1.095
HNSC
LUAD
LUSC	-0.45
non_ccRCC
PDAC
UCEC

PLA2G4A-Thr268
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	-1.076
LUAD	0.901
LUSC
non_ccRCC
PDAC
UCEC	0.174

PLA2G4A-Tyr396
Cancer	Intensity
BRCA	-0.707
COAD	0.707
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb